| 1 |
NCT02833792 |
Active, not recruiting |
Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease |
|
- Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution
- Other: Placebo
|
Interventional
|
Phase 2 |
- Stemedica Cell Technologies, Inc.
- Stemedica International SA
- Stemedica Cell Technologies, Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
|
40 |
All |
55 Years to 80 Years (Adult, Older Adult) |
NCT02833792 |
STEM105-M-AD |
|
June 2016 |
December 2019 |
June 2020 |
July 14, 2016 |
April 17, 2018 |
|
- University of California, Irvine Medical Center
Irvine, California, United States
|
|
| 2 |
NCT01297413 |
Active, not recruiting |
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke |
|
- Biological: Allogeneic adult mesenchymal bone marrow stem cells
|
Interventional
|
Phase 1
Phase 2 |
- Stemedica Cell Technologies, Inc.
- University of California, San Diego
- Mercy Gilbert Medical Center at AZ
- (and 3 more...)
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.
- National Institutes of Health Stroke Scale Score.
- Mini Mental Status Exam score.
- (and 2 more...)
|
38 |
All |
18 Years and older (Adult, Older Adult) |
NCT01297413 |
STEM 101-M |
|
February 2011 |
September 2017 |
December 2018 |
February 16, 2011 |
April 17, 2018 |
|
- Mercy Gilbert and Chandler Medical Center
Gilbert, Arizona, United States - University of California Irvine Department of Neurology
Orange, California, United States - University of California San Diego Division of Neurological Surgery
San Diego, California, United States
|
|
| 3 |
NCT01771679 |
Suspended |
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging |
- Chronic Effect of Ultraviolet Radiation on Photoaged Skin
- Dermatologic Disorders
|
- Biological: Allogeneic Mesenchymal Bone Marrow Cells
|
Interventional
|
Phase 1
Phase 2 |
- Stemedica Cell Technologies, Inc.
- StemCutis, LLC - A Stemedica Company
- Stemedica Cell Technologies, Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MSC Safety and Tolerability
- MSC Efficacy
|
29 |
All |
40 Years to 70 Years (Adult, Older Adult) |
NCT01771679 |
STEM 102-M |
|
July 2015 |
November 2018 |
May 2019 |
January 18, 2013 |
April 17, 2018 |
|
- eStudy Site
La Mesa, California, United States - Naval Medical Center San Diego
San Diego, California, United States
|
|
| 4 |
NCT01770613 |
Withdrawn |
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI) |
- ST Segment Elevation Myocardial Infarction (STEMI)
- Allogeneic Mesenchymal Bone Marrow Cells
|
|
Interventional
|
Phase 2 |
- Stemedica Cell Technologies, Inc.
- CardioCell LLC
- Stemedica Cell Technologies, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The safety and tolerability of aMBMC intravenous administration during the twelve month study period as determined by major adverse events MACE endpoint.
- The change from baseline on physical exam conducted at day 14 and at 1, 3, 6 and 12 months post-administration, as available:
- • LV end diastolic volume
- (and 5 more...)
|
0 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01770613 |
STEM 103-M-STEMI |
|
February 2013 |
May 2016 |
May 2017 |
January 18, 2013 |
April 27, 2017 |
|
- Mercy Gilbert and Chandler Medical Center
Gilbert, Arizona, United States - Emory University Hospital
Atlanta, Georgia, United States
|
|
| 5 |
NCT02467387 |
Unknown † |
A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure |
- Non-Ischemic Heart Failure
|
- Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
- Drug: Lactated Ringer's Solution
|
Interventional
|
Phase 2 |
- CardioCell LLC
- Stemedica Cell Technologies, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Safety will be evaluated by the incidence, severity, and relationship of AEs and SAEs
- Change in LVEF from baseline to day 90 post-initial infusion. After crossover phase all subjects will be evaluated for changes from the new baseline (Day 90 after initial infusion) to Day 90 post second infusion.
|
23 |
All |
18 Years and older (Adult, Older Adult) |
NCT02467387 |
STEM-104-M-CHF |
|
June 2014 |
April 2017 |
April 2017 |
June 10, 2015 |
April 20, 2016 |
|
- MedStar Washington Hospital Center
Washington, District of Columbia, United States - Emory University Hospital
Atlanta, Georgia, United States - Northwestern University Centers for Heart Failure Therapy
Chicago, Illinois, United States - (and 2 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: